tbuckley/cabot-search huggingface dataset:
New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF
Authors: Nathalie Massin
Journal: Human Reproduction Update (2016)

The advent of embryo and oocyte vitrification today gives reproductive specialists an opportunity to consider new strategies for improving the practice and results of IVF attempts. As the freezing of entire cohorts does not compromise, and may even improve, the results of IVF attempts, it is possible to break away from the standard sequence of stimulation-retrieval-transfer. The constraints associated with ovarian stimulation in relation to the potential harmful effects of the hormonal environment on endometrial receptivity can be avoided.This review will look at the new stimulation protocols where progesterone is used to block the LH surge. Thanks to 'freeze all' strategies, the increase in progesterone could actually be no longer a cause for concern. There are two ways of using progesterone, whether it be endogenous, as in luteal phase stimulation, or exogenous, as in the use of progesterone in the follicular phase i.e. progestin primed ovarian stimulation.A literature search was carried out (until September 2016) on MEDLINE. The following text words were utilized to generate the list of citations: progestin primed ovarian stimulation, luteal phase stimulation, luteal stimulation, duostim, double stimulation, random start. Articles and their references were then examined in order to identify other potential studies. All of the articles are reported in this review.The use of progesterone during ovarian stimulation is effective in blocking the LH surge, whether endogenous or exogenous, and it does not affect the number of oocytes collected or the quality of the embryos obtained. Its main constraint is that it requires total freezing and delayed transfer. A variety of stimulation protocols can be derived from these two methods, and their implications are discussed, from fertility preservation to ovarian response profiles to organization for the patients and clincs. These new regimens enable more flexibility and are of emerging interest in daily practice. However, their medical and economic significance remains to be demonstrated.The use of luteal phase or follicular phase protocols with progestins could rapidly develop in the context of oocyte donation and fertility preservation not related to oncology. Their place could develop even more in the general population of patients in IVF programs. The strategy of total freezing continues to develop, thanks to technical improvements, in particular vitrification and PGS on blastocysts, and thanks to studies showing improvements in embryo implantation when the transfer take place far removed from the hormonal changes caused by ovarian stimulation.
MA01.01 Detection of Lung Cancer and EGFR Mutations by Electronic Nose System
Authors: Dekel Shlomi, Manal Abud-Hawa, Ori Liran, Jair Bar, Naomi Gai Mor, Maya Ilouze, Amir Onn, Alon Ben-Nun, Hossam Haick, Nir Peled
Journal: Journal of Thoracic Oncology (2017)
23andMe, Big Data, and the Genetics of Depression
Authors: Jennifer Abbasi
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P1.08-079 Sulvage Surgery after Definitive Radiotherapy or Chemoradiotherapy for Lung Cancer
Authors: Naoya Yamasaki, Tomoshi Tsuchiya, Keitaro Matsumoto, Takuro Miyazaki, Ryotaro Kamohara, Tomohiro Obata, Daisuke Taniguchi, Takuya Yamasaki, Daisuke Nakamura, Kazuhiro Tabata, Takeshi Nagayasu
Journal: Journal of Thoracic Oncology (2017)
OA23.07 Analysis of Outcomes in US IRESSA Clinical Access Program (ICAP) Patients on Gefitinib for More Than 10 Years
Authors: Fred R. Hirsch, Lecia Sequist, Ira Gore, Meghan Campo, George Simon, Elisabeth Croft, Diana Devincenzo, Jiefen Munley, Dara Stein, Klaus Freivogel, Frangiscos Sifakis, Paul Bunn
Journal: Journal of Thoracic Oncology (2017)
Impaired natural killer cell functions in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations
Authors: Giovanna Tabellini, Donatella Vairo, Omar Scomodon, Nicola Tamassia, Rosalba Monica Ferraro, Ornella Patrizi, Sara Gasperini, Annarosa Soresina, Giuliana Giardino, Claudio Pignata, Vassilios Lougaris, Alessandro Plebani, Laura Dotta, Marco A. Cassatella, Silvia Parolini, Raffaele Badolato
Journal: Journal of Allergy and Clinical Immunology (2017)
Role of inoculum and mutant frequency on fosfomycin MIC discrepancies by agar dilution and broth microdilution methods in Enterobacteriaceae
Authors: M. Ballestero-Téllez, F. Docobo-Pérez, J.M. Rodríguez-Martínez, M.C. Conejo, M.S. Ramos-Guelfo, J. Blázquez, J. Rodríguez-Baño, A. Pascual
Journal: Clinical Microbiology and Infection (2017)
P2.04-005 WHO Classification and IASLC/ITMIG Staging Proposal in Thymic Tumors: Real-Life Assessment
Authors: Alexandra Meurgey, Nicolas Girard, Claire Merveilleux Du Vignaux, Jean-Michel Maury, François Tronc, Françoise Thivolet-Béjui, Lara Chalabreysse
Journal: Journal of Thoracic Oncology (2017)
P1.06-017 Observational Study on Prolonged Disease Stabilization in Advanced NSCLC EGFR WT/Unknown Patients Treated with Erlotinib in Second Line
Authors: Francesco Grossi, Agnese Montanino, Maria Rita Migliorino, Antonio Santo, Michele De Tursi, Angelo Delmonte, Fabiana Vitiello, Manlio Mencoboni, Vito D'Alessandro, Giampiero Romano, Erika Rijavec, Andrea Misino, Antonio Chella, Mario Roselli, Silvio Cavuto
Journal: Journal of Thoracic Oncology (2017)
The Non Receptor Transmembrane Tyrosine Kinase STYK1 Represents a Novel Lymphocyte Marker, Whose Expression Is Deregulated in Leukemia, and a Potential Molecular Druggable Target
Authors: Enrico Bracco, Valentina Rosso, Alessandra Balbo, Marco Lo Iacono, Stefano Mussino, Erika Deklic, Francesca Arruga, Sonia Carturan, Ilaria Defilippi, Francesca Messa, Cristina Panuzzo, Roberto Pedrola, Alessandro Morotti, Paolo Nicoli, Emanuela Messa, Antonia Rotolo, Ilaria Iacobucci, Giovanni Martinelli, Daniela Cilloni, Giuseppe Saglio
Journal: Blood (2008)
P1.08-020 The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC)
Authors: Nicholas Faris, Meredith Ray, Matthew Smeltzer, Carrie Fehnel, Cheryl Houston-Harris, Paul Levy, Chris Mutrie, Brad Wolf, Lawrence Deese, Lynn Wiggins, Vishal Sachdev, Sam Signore, Edward Robbins, Raymond Osarogiagbon
Journal: Journal of Thoracic Oncology (2017)
Doctors may make mistakes that are less obvious than lawyers' mistakes
Authors: R N Palmer
Journal: BMJ (1995)

EDITOR,—The sentiments expressed by Jean Ritchie and Sally Davies are laudable but raise two important matters which were not addressed by the authors.1

The authors refer to “mistakes” and to care which has “gone wrong” as though these were invariably self evident. A lawyer's missed deadline for issuing a writ or a motorist's dented vehicle may easily be recognised as evidence of mistake. It will readily be conceded that amputation of the wrong limb or a gross overdose of a …
P117 Pharmacy-led latent tb infection service: a success story
Authors: YO Abunga, M Day, SO Brij
Journal: Thorax (2016)

<h3>Introduction</h3> Previously we have reported good outcomes following a pilot study of latent TB infection (LTBI) assessment and treatment by a dedicated TB Pharmacist.<sup>1</sup> Since that time, the service has been imbedded within our local practice to reduce waiting times, improve chemoprophylaxis adherence, enhance treatment outcomes, and minimise adverse drug reactions whilst maintaining a high standard of care. In addition, patients with more complex medical needs requiring biological therapy are now not excluded from this service. <h3>Aim</h3> to review the safety and effectiveness of the Pharmacy-led Clinic <h3>Methods</h3> Medical records of all cases of LTBI seen by the TB Pharmacist were reviewed retrospectively. Data obtained included patient demographics, treatment ± side-effects and clinical outcomes. <h3>Results</h3> 206 patients with LTBI seen between Jan 2012 and December 2015 were identified (see Table 1). Contact tracing and the requirement for biological therapy were the commonest reasons for referral. 185 (89.8%) successfully completed treatment: 3 declined; 8 lost to follow up; 10 stopped due to side-effects. Significant drug side-effects included hepatitis, peripheral neuropathy, nausea and vomiting and only resulted in 2 non-completion, the rest were due to fatigue and headache. Of the 8 who stopped 1 developed active TB whilst on biological therapy. Patient satisfaction was good and patients would recommend this service to a friend or family member. <h3>Conclusion</h3> The LTBI Pharmacy-led clinic has been successfully implemented and incorporated into our local TB practice with good outcomes. Keeping with the Carter Review,<sup>2</sup> it is important to utilise the skills and knowledge of previously unrecognised clinical partners to deliver high quality care. Patients were happy to be seen by the pharmacists. Poly pharmacy patients appreciated time spent to simplify regime and manage potential interaction. <h3>References</h3> Abunga YO, Luwemba G, Brij SO. Diagnosis and management of TB: P59 Treatment and Drug Surveillance of Latent Tuberculosis Infections (LTBI) by a TB Pharmacist: A pilot study. <i>Thorax</i> 2012;<b>67</b>(Suppl 2):A88. Department of Health. Independent report – Productivity in NHS hospitals [ONLINE]. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/499229/Operational_productivity_A.pdf (Accessed 6 July 2016).
Acid suppressants are associated with increased risk of intestinal infections, study finds
Authors: Susan Mayor
Journal: BMJ (2017)

Taking commonly prescribed acid suppression drugs such as proton pump inhibitors (PPIs) is associated with an increased risk of intestinal infections, a population based study in Scotland has shown.1

Acid suppressants are increasingly prescribed in community and hospital settings in the UK. The drugs have been implicated as a possible risk factor for bacterial gastroenteritis, but studies have previously shown inconsistent findings.

The new study …
Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients
Authors: Antonio Palumbo, Sara Bringhen, Oreste Villani, Agostina Siniscalchi, Eleonora Russo, Giuseppina Uccello, Chiara Cerrato, Milena Gilestro, Davide Rossi, Mario Boccadoro
Journal: Blood (2012)
Objective Assessment of Pulmonary Embolism Can Be Deferred without Increased Risk.
Authors: Sergio Siragusa, Alessandra Malato, Antonino Giarratano, Francesco Falaschi, Fernando Porro, Maria Cristina Buonanno, Elena Maggi, Raffaela Anastasio, Lucio Lo Coco, Guglielmo Mariani
Journal: Blood (2005)
OA06.05 Proteomic Analysis of ERCC1 Predicts Benefit of Platinum Therapy in NSCLC: A Reevaluation of Samples from the TASTE Trial
Authors: Jean-Charles Soria, Ken Olaussen, Fabiola Cecchi, Eunkyung An, Christina Yau, Marie Wislez, Gérard Zalcman, Denis Moro-Sibilot, David Perol, Franck Morin, Benjamin Besse, Todd Hembrough
Journal: Journal of Thoracic Oncology (2017)
MA11.05 A Case-Control Study to Test the Use of ctDNA in the Early Detection of SCLC Reveals TP53 Mutations in Non-Cancer Controls
Authors: Lynnette Fernandez-Cuesta, Sandra Perdomo, Patrice Avogbe, Noémie Leblay, Tiffany Delhomme, Valerie Gaborieau, Behnoush Abedi-Ardekani, Estelle Chanudet, Magali Olivier, David Zaridze, Anush Mukeria, Marta Vilensky, Ivana Holcatova, Jerry Polesel, Lorenzo Simonato, Cristina Canova, Pagona Lagiou, Christian Brambilla, Elisabeth Brambilla, Graham Byrnes, Ghislaine Scelo, Florence Le Calvez-Kelm, Matthieu Foll, James Mckay, Paul Brennan
Journal: Journal of Thoracic Oncology (2017)
P79 Single Point Of Access Clinic (SPOAC): a new regional lung cancer pathway in new zealand
Authors: P Dawkins, J McWilliams, R Sullivan
Journal: Thorax (2016)

<h3>Aim</h3> A new pathway to enable quicker lung cancer diagnosis for the 4 district health boards within one of the cancer networks in New Zealand was developed incorporating rapid access clinics (RACs), with upfront PET-CT scans for those considered potentially curable at initial assessment. <h3>Methods</h3> In this 12-week pilot, patients graded as high suspicion of lung cancer were seen in RACs with spirometry, performance status assessment and available radiology (chest X-ray or CT scan). Those considered potentially curable by surgery or radiotherapy (FEV1 ≥1 litre, ECOG score &lt;2, no evidence of mediastinal lymphadenopathy or metastasis on imaging, no comorbidities precluding radical treatment) received an upfront PET-CT scan; those who were not received a standard CT scan if not already done. These protocols were based on the virtual model proposed by the Gleeson group, Oxford, UK.<sup>1</sup> Time through the pathway was measured and compared with historical data from the regional lung cancer database in a 6 month period the year before the pilot. <h3>Results</h3> One hundred and sixty five patients completed the pathway, of which 105 were found to have lung cancer. Forty one patients had upfront PET-CT scans; 30 were confirmed as lung cancer, 7 of which subsequently had palliative treatment. Eleven had non-lung cancer diagnoses (9 not cancer or nodule follow up; 1 metastasis; 1 other cancer). Seventeen patients had PET-CT scans later in the pathway, 4 of which subsequently had curative treatment. Median time from referral to first treatment was reduced by 16.7 days (patients with curative treatment intent 17.2 days and palliative treatment intent 12.7 days), significantly reducing both the time from referral to multidisciplinary meeting (MDM) and MDM to first treatment. Achievement of 62-day target referral to treatment targets was 85.7% compared with 56.6% in the historical data. <h3>Conclusion</h3> A regional lung cancer pathway incorporating RACs and upfront PET-CT scans for curative track patients resulted in improvements in diagnostic delays and 62-day treatment targets. These findings subsequently led to implementation of this pathway regionally. The study was funded by a New Zealand Ministry of Health project grant <h3>Reference</h3> Macpherson R, <i>et al</i>. A proposed new imaging pathway for patients with suspected lung cancer. <i>Clin Radiol</i> 2012;<b>67</b>(6):564–73.
P165 Surgical lung biopsy in the diagnosis of interstitial lung disease – where are we now?
Authors: L Brockbank, E Hilal, L Johns, M Walshaw, K Mohan
Journal: Thorax (2016)

<h3>Introduction</h3> With the advent of multidisciplinary team (MDT) working and new therapies in interstitial lung disease (ILD), diagnostic accuracy is increasingly important, and international guidelines<sup>1</sup> have reaffirmed the importance of surgical lung biopsy (SBx) where necessary. However, SBx has associated risks: to assess this further we looked at the diagnostic yield and complication rate of SBx carried out at our regional thoracic centre for patients with ILD. <h3>Methods</h3> We looked at all 104 SBxs carried out for ILD over 24 months between 2014–16, collecting data on the nature of the procedure, number of lobes sampled, complications encountered and mortality, and also whether the cases had been discussed at a regional ILD or local radiology MDT meeting prior to SBx. <h3>Results</h3> Seventy cases (67%) had been discussed prior to SBx (18 at an ILD MDT). Overall, mean age was 56 years, mean FEV1 79% predicted, FVC 84% predicted, RV 79% predicted, TLC 77% predicted, TLCO 56% predicted, and KCO 77% predicted. All but 3 procedures were carried out by VAT: the median number of lobes sampled was 2 (&gt;1 lobe in 86%), and diagnostic specimens were obtained in 97% (UIP 29%, RB-ILD and DIP 23%, HSP 12%, Sarcoid 10%, NSIP 7%, others 19%). For complications see Table. The mean length of stay was 5.2 days (range 1–44): in-hospital mortality and 30-day mortality were 1% and 3% respectively. <h3>Conclusion</h3> Although SBx is here to stay, it has significant morbidity and mortality. Transbronchial cryobiopsy may in the future sit alongside SBx in the diagnostic pathway for ILD, but in addition to offering low morbidity and mortality it must also offer a high diagnostic yield. <h3>Reference</h3> Travis WD, Costabel U, Hansell DM, <i>et al</i>. An official American Thoracic Society/European Respiratory Society Statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. <i>Am J Respir Crit Care Med</i> 2013;<b>188</b>:733–748.
P1.02-033 Mesenchymal Transformation is the Most Common Histomorphologic Changes in the Rebiopsy of Lung Cancer Patients with EGFR-TKI Resistance
Authors: Hyein Ahn, Hyun Jung Kwon, Eunhyang Park, Soo Young Park, Hyojin Kim, Se Hyun Kim, Jin-Haeng Chung
Journal: Journal of Thoracic Oncology (2017)
Use of Targeted Lymphocyte Depletion as a Personalized Approach to Improve Engraftment and Disease Control Following Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Unrelated Donors
Authors: Rachel B. Salit, Steven Z. Pavletic, Daniel H. Fowler, Jennifer Wilder, Kelly Bryant, Seth M. Steinberg, Frances T. Hakim, Michael R. Bishop
Journal: Blood (2010)
A Phase 1, Open-Label, Multi-Center, Multiple-Dose, Dose-Escalation Study of MDX-1342 in Patients with CD19-Positive Refractory/Relapsed Chronic Lymphocytic Leukemia.
Authors: Luis H Camacho, Robin Joyce, Jennifer R Brown, Asher Chanan-Khan, Philip C. Amrein, Albert Assad, Marion Carrigan
Journal: Blood (2009)
Analysis of TP53 Codon72, and p21 Codon31 Polymorphisms in CLL Patients Exposed to Ionizing Radiation Due to the Chernobyl NPP Accident
Authors: Nadiia Bilous, Iryna Abramenko, Anatoliy Chumak, Zoya Martina, Iryna Kryachok, Iryna Filonenko
Journal: Blood (2012)
P57 The cost-consequence of fluticasone furoate/vilanterol 100/25 MCG in the uk using the results from the COPD salford lung study
Authors: MT Driessen, S Barnfather, PJ Mulley, I I Boucot, T Ignacio, G van de Wetering
Journal: Thorax (2016)

<h3>Introduction</h3> To support clinicians and healthcare organisations in their decision making on Chronic Obstructive Pulmonary Disease (COPD) related care, there is a need for studies conducted in patient populations which are representative of everyday clinical practice. The Salford Lung Study (SLS) is an open label prospective randomised controlled effectiveness trial (RCT). The study was conducted between 2012 and 2015. SLS investigated the effectiveness and safety of initiating treatment with once daily fluticasone furoate/vilanterol 100/25 microgram (FF/VI) compared with continuing with usual COPD maintenance treatment (usual care) in patients with COPD in an everyday clinical setting. Compared with usual care, FF/VI statistically significantly reduced the annual rate of moderate and severe exacerbations by 8.41% (NNT = 7) in the intention to treat population (≥1 exacerbation in previous 3 y; n = 2799), and in patients with ≥1 exacerbation in previous 1 y; n = 2269). The current study estimates the potential economic impact of these results in a typical local UK payer environment. <h3>Methods</h3> A total of 1000 patients with COPD were included in an Excel based cost-consequence model. The model has a 1-year time-horizon. It was assumed that within one year the use of FF/VI would increase from 5% to 20%. Mean annual rates of moderate/severe exacerbations after twelve months for the ITT population were directly obtained from the RCT and included in the model (1.50 FF/VI and 1.64 usual care). Serious adverse events (SAEs) were excluded from the analysis. Costs were obtained from UK public sources and encompassed annual drug costs (£268 FF/VI; £491 usual care), and COPD exacerbation management costs (moderate £114; severe £2,053). <h3>Results</h3> Substituting usual care with FF/VI is likely to be associated with reduced COPD medication and exacerbation management costs. Total annual savings of £34,000 were obtained for a population of 1000 patients with COPD. <h3>Conclusion</h3> In an everyday UK clinical setting, substituting usual care with FF/VI in patients with COPD can result in substantial annual cost savings. These results are relevant for clinicians and health care organisations.
P114 Implications of NICE 2016 tuberculosis guidance for a TB contact screening service
Authors: AM Ray, S Oglesby, C Mullarkey, JP Watson
Journal: Thorax (2016)

<h3>Introduction</h3> NICE 2016 Tuberculosis guidance recommends significant changes in contact screening. Tuberculin Skin Test (TST) is advocated for diagnosis of latent tuberculosis infection (LTBI), with a positive TST redefined as 5mm regardless of BCG status, IGRA only to be used in diagnostic uncertainty, upper age for LTBI treatment raised from 35 to 65, and contact tracing no longer recommended for extra-pulmonary TB. We use a 2 step test, with IGRA for those with TST &gt; 10 mm in context of BCG, and treat LTBI on basis of IGRA result. We aimed to assess the implications for our service of adopting the new guidance. <h3>Methods</h3> We reviewed written and electronic records for all contacts screened in Leeds in 2015. NICE 2016 guidance was applied retrospectively to analyse the impact of each recommendation and the guidance as a whole. <h3>Results</h3> 216 contacts were screened. Full records were available for 193. 14 were treated for LTBI, 2 for active TB, and 6 contacts over 35 had X-ray follow up. 34 had TST &gt; 10 mm, an additional 13 had TST 5–9 mm. Of 34 with TST &gt; 10 mm, 14 (41%) had positive IGRA. 97/193 (50%) were contacts of extrapulmonary tuberculosis. 4 of these were treated for LTBI, but 21 had TST &gt; 5 mm. Using TST &gt; 5 mm cut off would increase the number of IGRA tests from 34 to 46. Treating on basis of TST alone would increase the number given chemoprophylaxis from 14 to 46. Stopping screening for contacts of extrapulmonary cases would reduce the number screened by 50% and the number treated from 46 to 29. However, this would be at the cost of missing at least 4/14 LTBI with positive IGRA. <h3>Conclusion</h3> Adopting the new NICE guidance in full would reduce the number screened but significantly increase the numbers treated for LTBI. Using the 2 step test with a TST cut off of 5mm would modestly increase the number of IGRA tests but would be unlikely to have a large impact on the number treated. Stopping screening for contacts of extrapulmonary TB would reduce the screening workload by 50% but reduce the number of LTBI cases diagnosed by 29%.
P3.02b-054 EGFR Mutation Profile in Newly Diagnosed Lung Adenocarcinoma in Persahabatan Hospital, Jakarta-Indonesia
Authors: Sita Laksmi Andarini, Jamal Zaini, Achmad Hudoyo, Ahmad Utomo, Elisna Syahruddin, Heriawaty Hidajat
Journal: Journal of Thoracic Oncology (2017)